View Item 

Show simple item record

Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial
dc.contributor.authorDobre, Danielaen_US
dc.contributor.authorRossignol, Patricken_US
dc.contributor.authorMurin, Janen_US
dc.contributor.authorParkhomenko, Alexanderen_US
dc.contributor.authorLamiral, Zohraen_US
dc.contributor.authorKrum, Henryen_US
dc.contributor.authorVeldhuisen, Dirk J.en_US
dc.contributor.authorPitt, Bertramen_US
dc.contributor.authorZannad, Faiezen_US
dc.date.accessioned2014-02-11T17:57:08Z
dc.date.available2014-04-02T15:08:07Zen_US
dc.date.issued2013-02en_US
dc.identifier.citationDobre, Daniela; Rossignol, Patrick; Murin, Jan; Parkhomenko, Alexander; Lamiral, Zohra; Krum, Henry; Veldhuisen, Dirk J.; Pitt, Bertram; Zannad, Faiez (2013). "Statin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trial." European Journal of Heart Failure 15(2): 221-227. <http://hdl.handle.net/2027.42/102677>en_US
dc.identifier.issn1388-9842en_US
dc.identifier.issn1879-0844en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/102677
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherEPHESUS Trialen_US
dc.subject.otherAcute Myocardial Infarctionen_US
dc.subject.otherStatin Therapyen_US
dc.subject.otherAcute Heart Failureen_US
dc.titleStatin therapy and clinical outcomes in myocardial infarction patients complicated by acute heart failure: insights from the EPHESUS trialen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelCardiovascular Medicineen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid22872593en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/102677/1/ejhfhfs128.pdf
dc.identifier.doi10.1093/eurjhf/hfs128en_US
dc.identifier.sourceEuropean Journal of Heart Failureen_US
dc.identifier.citedreferenceTreasure CB Klein JL Weintraub WS Talley JD Stillabower ME Kosinski AS Zhang J Boccuzzi SJ Cedarholm JC Alexander RW Beneficial effects of cholesterol‐lowering therapy on the coronary endothelium in patients with coronary artery disease N Engl J Med 1995 332 481 487en_US
dc.identifier.citedreferenceKrum H Latini R Maggioni AP Anand I Masson S Carretta E Ingrilli F Pettinati G Glazer R Tognoni G Cohn J Statins and symptomatic chronic systolic heart failure: a post‐hoc analysis of 5010 patients enrolled in Val‐HeFT Int J Cardiol 2007 119 48 53en_US
dc.identifier.citedreferenceKrum H McMurray JJ Statins and chronic heart failure: do we need a large‐scale outcome trial? J Am Coll Cardiol 2002 39 1567 1573en_US
dc.identifier.citedreferenceKjekshus J Apetrei E Barrios V Bohm M Cleland JG Cornel JH Dunselman P Fonseca C Goudev A Grande P Gullestad L Hjalmarson A Hradec J Janosi A Kamensky G Komajda M Korewicki J Kuusi T Mach F Mareev V McMurray JJ Ranjith N Schaufelberger M Vanhaecke J van Veldhuisen DJ Waagstein F Wedel H Wikstrand J Rosuvastatin in older patients with systolic heart failure N Engl J Med 2007 357 2248 2261en_US
dc.identifier.citedreferenceTavazzi L Maggioni AP Marchioli R Barlera S Franzosi MG Latini R Lucci D Nicolosi GL Porcu M Tognoni G Effect of rosuvastatin in patients with chronic heart failure (the GISSI‐HF trial): a randomised, double‐blind, placebo‐controlled trial Lancet 2008 372 1231 1239en_US
dc.identifier.citedreferencePitt B Remme W Zannad F Neaton J Martinez F Roniker B Bittman R Hurley S Kleiman J Gatlin M Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 2003 348 1309 1321en_US
dc.identifier.citedreferencePitt B Williams G Remme W Martinez F Lopez‐Sendon J Zannad F Neaton J Roniker B Hurley S Burns D Bittman R Kleiman J The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post‐AMI Heart Failure Efficacy and Survival Study Cardiovasc Drugs Ther 2001 15 79 87en_US
dc.identifier.citedreferenceDobre D DeJongste MJ Lucas C Cleuren G van Veldhuisen DJ Ranchor AV Haaijer‐Ruskamp F Effectiveness of beta‐blocker therapy in daily practice patients with advanced chronic heart failure; is there an effect‐modification by age? Br J Clin Pharmacol 2007 63 356 364en_US
dc.identifier.citedreferenceFlather MD Shibata MC Coats AJ Van Veldhuisen DJ Parkhomenko A Borbola J Cohen‐Solal A Dumitrascu D Ferrari R Lechat P Soler‐Soler J Tavazzi L Spinarova L Toman J Bohm M Anker SD Thompson SG Poole‐Wilson PA Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J 2005 26 215 225en_US
dc.identifier.citedreferenceHoffman RM Psaty BM Kronmal RA Modifiable risk factors for incident heart failure in the coronary artery surgery study Arch Intern Med 1994 154 417 423en_US
dc.identifier.citedreferenceHorwich TB Hamilton MA Maclellan WR Fonarow GC Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure J Card Fail 2002 8 216 224en_US
dc.identifier.citedreferenceKronmal RA Cain KC Ye Z Omenn GS Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data Arch Intern Med 1993 153 1065 1073en_US
dc.identifier.citedreferenceKalantar‐Zadeh K Block G Horwich T Fonarow GC Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure J Am Coll Cardiol 2004 43 1439 1444en_US
dc.identifier.citedreferenceAnderson TJ Meredith IT Yeung AC Frei B Selwyn AP Ganz P The effect of cholesterol‐lowering and antioxidant therapy on endothelium‐dependent coronary vasomotion N Engl J Med 1995 332 488 493en_US
dc.identifier.citedreferenceNode K Fujita M Kitakaze M Hori M Liao JK Short‐term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy Circulation 2003 108 839 843en_US
dc.identifier.citedreferenceRossignol P Cleland JG Bhandari S Tala S Gustafsson F Fay R Lamiral Z Dobre D Pitt B Zannad F Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post‐Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Circulation 2011 125 271 279en_US
dc.identifier.citedreferenceBaller D Notohamiprodjo G Gleichmann U Holzinger J Weise R Lehmann J Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol‐lowering therapy in patients with early stages of coronary atherosclerosis Circulation 1999 99 2871 2875en_US
dc.identifier.citedreferenceGuethlin M Kasel AM Coppenrath K Ziegler S Delius W Schwaiger M Delayed response of myocardial flow reserve to lipid‐lowering therapy with fluvastatin Circulation 1999 99 475 481en_US
dc.identifier.citedreferencevan der Harst P, Voors AA, van Gilst WH, Bohm M, van Veldhuisen DJ Statins in the treatment of chronic heart failure: biological and clinical considerations Cardiovasc Res 2006 71 443 454en_US
dc.identifier.citedreferencevan der Harst P, Slart RH, Tio RA, Dunselman PH, Willemsen AT, van den Heuvel AF, Voors AA, van Veldhuisen DJ Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study) Am J Cardiol 2010 105 517 521en_US
dc.identifier.citedreferenceSattar N Preiss D Murray HM Welsh P Buckley BM de Craen AJ Seshasai SR McMurray JJ Freeman DJ Jukema JW Macfarlane PW Packard CJ Stott DJ Westendorp RG Shepherd J Davis BR Pressel SL Marchioli R Marfisi RM Maggioni AP Tavazzi L Tognoni G Kjekshus J Pedersen TR Cook TJ Gotto AM Clearfield MB Downs JR Nakamura H Ohashi Y Mizuno K Ray KK Ford I Statins and risk of incident diabetes: a collaborative meta‐analysis of randomised statin trials Lancet 2010 375 735 742en_US
dc.identifier.citedreferenceAlberton M Wu P Druyts E Briel M Mills EJ Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta‐analysis QJM 2012 105 145 157en_US
dc.identifier.citedreferencePreiss D Seshasai SR Welsh P Murphy SA Ho JE Waters DD DeMicco DA Barter P Cannon CP Sabatine MS Braunwald E Kastelein JJ de Lemos JA Blazing MA Pedersen TR Tikkanen MJ Sattar N Ray KK Risk of incident diabetes with intensive‐dose compared with moderate‐dose statin therapy: a meta‐analysis JAMA 2011 305 2556 2564en_US
dc.identifier.citedreferenceButler J Arbogast PG BeLue R Daugherty J Jain MK Ray WA Griffin MR Outpatient adherence to beta‐blocker therapy after acute myocardial infarction J Am Coll Cardiol 2002 40 1589 1595en_US
dc.identifier.citedreferenceButler J Arbogast PG Daugherty J Jain MK Ray WA Griffin MR Outpatient utilization of angiotensin‐converting enzyme inhibitors among heart failure patients after hospital discharge J Am Coll Cardiol 2004 43 2036 2043en_US
dc.identifier.citedreferenceRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994 344 1383 1389en_US
dc.identifier.citedreferencePrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels The Long‐Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N Engl J Med 1998 339 1349 1357en_US
dc.identifier.citedreferenceHeart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: a randomised placebo‐controlled trial Lancet 2002 360 7 22en_US
dc.identifier.citedreferenceSchwartz GG Olsson AG Ezekowitz MD Ganz P Oliver MF Waters D Zeiher A Chaitman BR Leslie S Stern T Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 2001 285 1711 1718en_US
dc.identifier.citedreferenceCannon CP McCabe CH Belder R Breen J Braunwald E Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)‐TIMI 22 trial Am J Cardiol 2002 89 860 861en_US
dc.identifier.citedreferencePasceri V Patti G Nusca A Pristipino C Richichi G Di Sciascio G Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study Circulation 2004 110 674 678en_US
dc.identifier.citedreferencePatti G Chello M Candura D Pasceri V D'Ambrosio A Covino E Di Sciascio G Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA‐3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study Circulation 2006 114 1455 1461en_US
dc.identifier.citedreferencePedersen TR Faergeman O Kastelein JJ Olsson AG Tikkanen MJ Holme I Larsen ML Bendiksen FS Lindahl C Szarek M Tsai J High‐dose atorvastatin vs usual‐dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 2005 294 2437 2445en_US
dc.identifier.citedreferenceRamasubbu K Estep J White DL Deswal A Mann DL Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy J Am Coll Cardiol 2008 51 415 426en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhfhfs128.pdf
Size:
172.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.